U.S. Markets open in 21 mins
  • S&P Futures

    3,317.25
    -65.75 (-1.94%)
     
  • Dow Futures

    26,741.00
    -624.00 (-2.28%)
     
  • Nasdaq Futures

    11,396.75
    -191.25 (-1.65%)
     
  • Russell 2000 Futures

    1,552.60
    -36.40 (-2.29%)
     
  • Crude Oil

    37.75
    -1.82 (-4.60%)
     
  • Gold

    1,882.00
    -29.90 (-1.56%)
     
  • Silver

    23.73
    -0.84 (-3.42%)
     
  • EUR/USD

    1.1733
    -0.0057 (-0.4810%)
     
  • 10-Yr Bond

    0.7490
    -0.0290 (-3.73%)
     
  • Vix

    37.94
    +5.48 (+16.88%)
     
  • GBP/USD

    1.2947
    -0.0094 (-0.7186%)
     
  • USD/JPY

    104.3480
    -0.1460 (-0.1397%)
     
  • BTC-USD

    13,316.36
    -393.66 (-2.87%)
     
  • CMC Crypto 200

    263.68
    +2.39 (+0.92%)
     
  • FTSE 100

    5,603.21
    -125.78 (-2.20%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Recap: DarioHealth Q1 Earnings

Benzinga Insights
·1 min read

Shares of DarioHealth (NASDAQ:DRIO) remained unaffected at $7.95 after the company reported Q1 results.

Quarterly Results

Earnings per share fell 946.67% year over year to ($1.57), which missed the estimate of ($0.75).

Revenue of $1,667,000 less by 25.65% year over year, which missed the estimate of $1,750,000.

Guidance

DarioHealth hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 12, 2020

View more earnings on DRIO

Time: 08:04 PM ET

Webcast URL: https://www.webcaster4.com/Webcast/Page/2224/34665

Technicals

Company's 52-week high was at $11.25

52-week low: $0.20

Price action over last quarter: Up 109.21%

Company Overview

DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.